Standout Papers

Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent... 1999 2026 2008 2017 677
  1. Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer (1999)
    Joachim von Pawel, Joan H. Schiller et al. Journal of Clinical Oncology

Citation Impact

6 from Science/Nature 53 standout
Sub-graph 1 of 22

Citing Papers

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
Selective Inhibition of Na V 1.8 with VX-548 for Acute Pain
2023 Standout
2 intermediate papers

Works of Stephen Lane being referenced

Phase II Study to Evaluate the Safety and Efficacy of the Oral Neurokinin-1 Receptor Antagonist Casopitant (GW679769) Administered with Ondansetron for the Prevention of Postoperative and Postdischarge Nausea and Vomiting in High-risk Patients
2010
Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer
1999 Standout

Author Peers

Author Oncology Molecular Biology Reproductive Medicine Epidemiology Last Decade Papers Cites
Stephen Lane 1379 924 173 719 30 1.7k
Ken Gale 1 51 512
In Hyung Baek 3 31 601
Jens Schroeder 9 38 1 8 127
Qinglong Tan 5 47 1 15 681
Minnesh Bipath 6 259

All Works

Loading papers...

Rankless by CCL
2026